Chapter/Section Purchase

1 PD-1 and PD-L1 Inhibitors Market Overview
1.1 Product Overview and Scope of PD-1 and PD-L1 Inhibitors
1.2 PD-1 and PD-L1 Inhibitors Segment by Type
1.2.1 Global PD-1 and PD-L1 Inhibitors Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 PD-1 and PD-L1 Inhibitors Segment by Application
1.3.1 Global PD-1 and PD-L1 Inhibitors Sales Comparison by Application: (2021-2027)
1.3.2 Solid Tumors
1.3.3 Blood-related Tumors
1.4 Global PD-1 and PD-L1 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global PD-1 and PD-L1 Inhibitors Revenue 2016-2027
1.4.2 Global PD-1 and PD-L1 Inhibitors Sales 2016-2027
1.4.3 PD-1 and PD-L1 Inhibitors Market Size by Region: 2016 Versus 2021 Versus 2027

2 PD-1 and PD-L1 Inhibitors Market Competition by Manufacturers
2.1 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Manufacturers (2016-2021)
2.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Manufacturers (2016-2021)
2.3 Global PD-1 and PD-L1 Inhibitors Average Price by Manufacturers (2016-2021)
2.4 Manufacturers PD-1 and PD-L1 Inhibitors Manufacturing Sites, Area Served, Product Type
2.5 PD-1 and PD-L1 Inhibitors Market Competitive Situation and Trends
2.5.1 PD-1 and PD-L1 Inhibitors Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest PD-1 and PD-L1 Inhibitors Players Market Share by Revenue
2.5.3 Global PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 PD-1 and PD-L1 Inhibitors Retrospective Market Scenario by Region
3.1 Global PD-1 and PD-L1 Inhibitors Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global PD-1 and PD-L1 Inhibitors Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
3.3.1 North America PD-1 and PD-L1 Inhibitors Sales by Country
3.3.2 North America PD-1 and PD-L1 Inhibitors Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
3.4.1 Europe PD-1 and PD-L1 Inhibitors Sales by Country
3.4.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific PD-1 and PD-L1 Inhibitors Market Facts & Figures by Region
3.5.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Region
3.5.2 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
3.6.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Country
3.6.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
3.7.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country
3.7.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global PD-1 and PD-L1 Inhibitors Historic Market Analysis by Type
4.1 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2016-2021)
4.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2016-2021)
4.3 Global PD-1 and PD-L1 Inhibitors Price by Type (2016-2021)

5 Global PD-1 and PD-L1 Inhibitors Historic Market Analysis by Application
5.1 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2016-2021)
5.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2016-2021)
5.3 Global PD-1 and PD-L1 Inhibitors Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Merck PD-1 and PD-L1 Inhibitors Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Bristol-Myers Squibb
6.2.1 Bristol-Myers Squibb Corporation Information
6.2.2 Bristol-Myers Squibb Description and Business Overview
6.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio
6.2.5 Bristol-Myers Squibb Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Roche PD-1 and PD-L1 Inhibitors Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 AstraZeneca
6.4.1 AstraZeneca Corporation Information
6.4.2 AstraZeneca Description and Business Overview
6.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio
6.4.5 AstraZeneca Recent Developments/Updates
6.5 Ono Pharmaceutical
6.5.1 Ono Pharmaceutical Corporation Information
6.5.2 Ono Pharmaceutical Description and Business Overview
6.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio
6.5.5 Ono Pharmaceutical Recent Developments/Updates
6.6 Regeneron
6.6.1 Regeneron Corporation Information
6.6.2 Regeneron Description and Business Overview
6.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio
6.6.5 Regeneron Recent Developments/Updates
6.7 Innovent
6.6.1 Innovent Corporation Information
6.6.2 Innovent Description and Business Overview
6.6.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Innovent PD-1 and PD-L1 Inhibitors Product Portfolio
6.7.5 Innovent Recent Developments/Updates
6.8 Hengrui Medicine
6.8.1 Hengrui Medicine Corporation Information
6.8.2 Hengrui Medicine Description and Business Overview
6.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio
6.8.5 Hengrui Medicine Recent Developments/Updates
6.9 Junshi Biosciences
6.9.1 Junshi Biosciences Corporation Information
6.9.2 Junshi Biosciences Description and Business Overview
6.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio
6.9.5 Junshi Biosciences Recent Developments/Updates
6.10 Merck KGaA
6.10.1 Merck KGaA Corporation Information
6.10.2 Merck KGaA Description and Business Overview
6.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio
6.10.5 Merck KGaA Recent Developments/Updates

7 PD-1 and PD-L1 Inhibitors Manufacturing Cost Analysis
7.1 PD-1 and PD-L1 Inhibitors Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of PD-1 and PD-L1 Inhibitors
7.4 PD-1 and PD-L1 Inhibitors Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 PD-1 and PD-L1 Inhibitors Distributors List
8.3 PD-1 and PD-L1 Inhibitors Customers

9 PD-1 and PD-L1 Inhibitors Market Dynamics
9.1 PD-1 and PD-L1 Inhibitors Industry Trends
9.2 PD-1 and PD-L1 Inhibitors Growth Drivers
9.3 PD-1 and PD-L1 Inhibitors Market Challenges
9.4 PD-1 and PD-L1 Inhibitors Market Restraints

10 Global Market Forecast
10.1 PD-1 and PD-L1 Inhibitors Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of PD-1 and PD-L1 Inhibitors by Type (2022-2027)
10.1.2 Global Forecasted Revenue of PD-1 and PD-L1 Inhibitors by Type (2022-2027)
10.2 PD-1 and PD-L1 Inhibitors Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of PD-1 and PD-L1 Inhibitors by Application (2022-2027)
10.2.2 Global Forecasted Revenue of PD-1 and PD-L1 Inhibitors by Application (2022-2027)
10.3 PD-1 and PD-L1 Inhibitors Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of PD-1 and PD-L1 Inhibitors by Region (2022-2027)
10.3.2 Global Forecasted Revenue of PD-1 and PD-L1 Inhibitors by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer